As of , Quick Heal Technologies Ltd (IT - Software) has a deep value score of 27/100 (rated Weak). Earnings are accelerating. 1Y return vs Nifty 500: -28%.
Based on Q3 FY26 earnings • Updated Apr 18, 2026
What: Enterprise Revenue Share: 45% of 9M FY26 revenue
“4 years back, our Consumer business was 18% and our Enterprise business 20%. But over the last couple of quarters, now it is 60-40.”
What: New Order Value: ₹64 Cr
Impact: ₹64 Cr over 5 years
“INR 64 Cr Order received: 5-year fulfillment period for implementation of integrated cybersecurity solutions”
What: DPDP Market Potential: New market creation
“this law is much more comprehensive and guidelines are coming... scope for a product like data privacy product that we just launched”
What: Enterprise Revenue growth of 37.1% YoY
“Enterprise Revenue 37.1% YoY... Enterprise business continued to grow steadily, driven by strong partners, innovative product launches”
Earnings deceleration risks from management commentary
Trigger: The law is passed but implementation and enforcement guidelines are still pending.
Management view: Onboarding early adopters for POCs to be ready when enforcement begins.
Monitor: regulatory
Trigger: Changing consumer behavior and built-in OS security features reducing demand for standalone AV.
Impact: PAT impact: -21.2% YoY revenue hit in Consumer segment
Management view: Launching AntiFraud.AI to pivot from pure AV to broader digital protection.
Monitor: cyber
Key quotes from recent conference calls
“Having said that, in last couple of quarters, we are in the similar range of around INR 30 crores to INR 35 crores in a quarter [Previous R&D Expense Range guidance]”
“Positioning AntiFraud.AI to tackle the financial frauds... Focus towards maintaining our market share in AV segment [Initiative: AntiFraud.AI Launch]”
“that is something that will create a new market altogether for a product like complying for DPDP [Initiative: DPDP Compliance Products]”
“But then, of course, the law is still delayed. It's not yet completely implemented on the ground. [Risk (regulatory): MEDIUM]”
Headline numbers from the latest earnings call
Revenue
₹71.5 Cr
Why: Revenue growth was driven by a 37.1% increase in Enterprise revenue, offset by a 21.2% decline in the Consumer segment.
The company is seeing a structural shift as Enterprise revenue now matches Consumer revenue.
EBITDA
₹0.5 Cr
Why: EBITDA improved due to optimized R&D investments through automation and AI, despite a decline in high-margin consumer revenue.
Margins remain thin at 0.6% as the company transitions its business mix.
PAT
₹6.6 Cr
Why: PAT growth was significantly aided by a sharp increase in Other Income to ₹9.0 Cr compared to ₹4.9 Cr in the previous year.
The massive YoY percentage jump is due to a very low base of ₹0.1 Cr in Q3 FY25.
Other Highlights
• Order Book stands at ₹80 Cr+
• Deferred Revenue increased to ~₹20 Cr
• Received ₹64 Cr order for integrated cybersecurity solutions with a 5-year fulfillment period
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Enterprise Revenue % of Total
45%
Why: Rapid growth in Seqrite business vs decline in Quick Heal consumer business.
Deferred Revenue
₹20 Cr
Why: Increased multi-year deal bookings in the Enterprise segment.
Order Book
₹80 Cr
Why: Strong traction in Government and Enterprise multi-year contracts.
R&D as % of Revenue
41.1%
Why: Management is optimizing R&D spend through AI and automation.
Enterprise Revenue Growth (YoY)
37.1%
Why: Driven by mid-market capture and new product launches.
Consumer Revenue Growth (YoY)
-21.2%
Why: Structural decline in the global consumer antivirus market.
Enterprise Cloud Revenue Mix
35%
Why: Increasing adoption of cloud-based security solutions over on-premise.
Enterprise Repeat Customer Rate
80%+
Why: High stickiness in enterprise cybersecurity contracts.
Forward-looking targets from management for Long-term
Capex Plan
₹179 Cr
Margins will certainly improve as the business grows.
₹179 Cr
Potential M&A or strategic acquisitions
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +1% | -6% | Inflection Up |
| PAT (Net Profit) | +5909% | -50% | Inflection Up |
| OPM | 0.6% | +597 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Quick Heal Technologies Ltd has a deep value score of 27/100 (rated Weak). This score is calculated from three components
Quick Heal Technologies Ltd's quarterly profit (PAT) growth trajectory
Quick Heal Technologies Ltd is underperforming the market despite improving earnings — this is the core deep value thesis
Quick Heal Technologies Ltd's earnings momentum is Accelerating — profit growth is speeding up.
Quick Heal Technologies Ltd's valuation metrics
Quick Heal Technologies Ltd's revenue and margin trends
Quick Heal Technologies Ltd's trailing twelve month (TTM) performance
Quick Heal Technologies Ltd key facts
Quick Heal Technologies Ltd shows limited deep value signals currently — score is 27/100 (Weak). Monitor for improvement.
Other deep value stocks in IT - Software
IT - Software deep value sector overview
Deep value investing studies stocks that are underperforming the market despite showing improving fundamentals. The thesis is that the market has not yet recognized the earnings recovery, creating a potential valuation gap. It requires patience — recovery can take several quarters.
The deep value score (0-100) combines three factors:
- Earnings (0-40 pts): PAT growth across last 3 quarters, acceleration, and consecutive growth - Underperformance (0-35 pts): How much the stock trails Nifty 500 over 1Y, 6M, 3M (deeper underperformance = higher score) - Quality (0-25 pts): Revenue growth, margin trends, and valuation metrics (PEG, P/B)
Higher score indicates a stronger contrarian research signal.
Quick Heal Technologies Ltd has 4 key growth catalysts identified from recent earnings analysis
Quick Heal Technologies Ltd has 2 key risks worth monitoring
In Q3 FY26, Quick Heal Technologies Ltd's management highlighted
The above FAQs are generated from publicly available earnings data. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
